Display options
Cite
Ouoba S, Okimoto M, Nagashima S, et al. Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients. J Med Virol. 2021;doi: 10.1002/jmv.27518.
Ouoba, S., Okimoto, M., Nagashima, S., Kitahara, Y., Miwata, K., Ko, K., E, B., Sugiyama, A., Takahashi, K., Sakaguchi, T., Takafuta, T., & Tanaka, J. (2021). Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients. Journal of medical virology, . https://doi.org/10.1002/jmv.27518
Ouoba, Serge, et al. "Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients." Journal of medical virology vol. (2021). doi: https://doi.org/10.1002/jmv.27518
Ouoba S, Okimoto M, Nagashima S, Kitahara Y, Miwata K, Ko K, E B, Sugiyama A, Takahashi K, Sakaguchi T, Takafuta T, Tanaka J. Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients. J Med Virol. 2021 Dec 12; doi: 10.1002/jmv.27518. Epub 2021 Dec 12. PMID: 34897741.
Copy Download .nbib Format: NLM
Share it on

J Med Virol. 2021 Dec 12; doi: 10.1002/jmv.27518. Epub 2021 Dec 12.

Sequential dynamics of virological and serological changes in the serum of SARS-CoV-2 infected patients.

Journal of medical virology

Serge Ouoba, Mafumi Okimoto, Shintaro Nagashima, Yoshihiro Kitahara, Kei Miwata, Ko Ko, Bunthen E, Aya Sugiyama, Kazuaki Takahashi, Takemasa Sakaguchi, Toshiro Takafuta, Junko Tanaka

Affiliations

  1. Department of Epidemiology, Infectious Disease Control and Prevention, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
  2. Unité de Recherche Clinique de Nanoro (URCN), Institut de Recherche en Science de la Santé (IRSS), Nanoro, Burkina Faso.
  3. Hiroshima City Funairi Citizens Hospital, Hiroshima, Japan.
  4. Payment Certification Agency, Ministry of Health, Phnom Penh, Cambodia.
  5. Department of Virology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.

PMID: 34897741 DOI: 10.1002/jmv.27518

Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral load dynamics in respiratory samples have been studied, but knowledge about changes in serial serum samples of infected patients in relation to their immunological response is lacking. We investigated the dynamics of SARS-CoV-2 viral load and antibody response in sequential serum of coronavirus disease 2019 (COVID-19) patients and attempted to culture the virus in the serum. A total of 81 sequential serum samples from 10 confirmed COVID-19 patients (5 with mild and 5 with moderate symptoms) were analyzed. Samples were collected during hospitalization and after discharge (median follow-up of 35 days). SARS-CoV-2 ribonucleic acid in the serum was detected by real-time polymerase chain reaction. Total antibody and IgG to SARS-CoV-2 Spike protein were analyzed by Chemiluminescent Immunoassays, and neutralizing antibodies were detected using a Surrogate Virus Neutralization Test. Viremia was observed in all cases at admission, and viral copy gradually dropped to undetectable levels in patients with mild symptoms but fluctuated and remained persistent in moderate cases. The viral culture of samples with the highest viral load for each patient did not show any cytopathic change. The antibody response was faster and higher in moderate cases. This study provides a basic clue for infectious severity-dependent immune response, viremia, and antibody acquisition pattern.

© 2021 The Authors. Journal of Medical Virology Published by Wiley Periodicals LLC.

Keywords: COVID-19; SARS-CoV-2; antibody; serum; viral culture; viremia

References

  1. World Health Organization. WHO coronavirus disease (COVID-19) dashboard with vaccination data. Published 2021. Accessed August 31, 2021. https://covid19.who.int/ - PubMed
  2. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. JAMA. 2020. 2020;323(18):1843-1844. doi:10.1001/JAMA.2020.3786 - PubMed
  3. Cappy P, Candotti D, Sauvage V, et al. No evidence of SARS-CoV-2 transfusion transmission despite RNA detection in blood donors showing symptoms after donation. Blood. 2020;136(16):1888-1891. doi:10.1182/BLOOD.2020008230 - PubMed
  4. Andersson MI, Arancibia-Carcamo CV, Auckland K, et al. SARS-CoV-2 RNA detected in blood products from patients with COVID-19 is not associated with infectious virus. Wellcome Open Res. 2020;5:5. doi:10.12688/WELLCOMEOPENRES.16002.2 - PubMed
  5. National Institutes of Health. COVID-19 Treatment Guidelines. Published 2021. Accessed August 31, 2021. https://www.covid19treatmentguidelines.nih.gov/ - PubMed
  6. Ko K, Nagashima S, Bunthen E, et al. Molecular characterization and the mutation pattern of SARS-CoV-2 during first and second wave outbreaks in Hiroshima, Japan. PLoS One. 2021;16(2):e0246383. doi:10.1371/journal.pone.0246383 - PubMed
  7. Kitagawa H, Nomura T, Nazmul T, et al. Effectiveness of 222-nm ultraviolet light on disinfecting SARS-CoV-2 surface contamination. Am J Infect Control. 2021;49(3):299-301. doi:10.1016/J.AJIC.2020.08.022 - PubMed
  8. Tang K, Wu L, Luo Y, Gong B. Quantitative assessment of SARS-CoV-2 RNAemia and outcome in patients with coronavirus disease 2019. J Med Virol. 2021;93(5):3165-3175. doi:10.1002/JMV.26876 - PubMed
  9. Rodríguez-Serrano DA, Roy-Vallejo E, Zurita Cruz ND, et al. Detection of SARS-CoV-2 RNA in serum is associated with increased mortality risk in hospitalized COVID-19 patients. Sci Rep. 2021;11(1):13134. doi:10.1038/s41598-021-92497-1 - PubMed
  10. Imai K, Kitagawa Y, Tabata S, et al. Antibody response patterns in COVID-19 patients with different levels of disease severity in Japan. J Med Virol. 2021;93(5):3211-3218. doi:10.1002/JMV.26899 - PubMed

Publication Types

Grant support